Gregory Lucier Acquires 27,555 Shares of DENTSPLY SIRONA (NASDAQ:XRAY) Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Gregory Lucier acquired 27,555 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was bought at an average cost of $14.24 per share, for a total transaction of $392,383.20. Following the completion of the purchase, the director owned 27,555 shares of the company’s stock, valued at $392,383.20. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

DENTSPLY SIRONA Stock Performance

NASDAQ:XRAY opened at $13.44 on Thursday. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.85 and a fifty-two week high of $17.18. The company has a 50 day simple moving average of $12.56 and a two-hundred day simple moving average of $12.48. The company has a market capitalization of $2.68 billion, a PE ratio of -4.48, a P/E/G ratio of 1.56 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The firm had revenue of $961.00 million during the quarter, compared to the consensus estimate of $926.40 million. During the same period in the prior year, the company posted $0.26 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were given a $0.16 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $0.64 annualized dividend and a dividend yield of 4.8%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is -21.33%.

Wall Street Analyst Weigh In

Several research firms recently commented on XRAY. Zacks Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday. Mizuho increased their price target on DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research note on Wednesday, January 21st. Stifel Nicolaus set a $13.00 target price on shares of DENTSPLY SIRONA in a research report on Thursday, November 6th. Finally, Robert W. Baird increased their target price on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Three equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $14.42.

Trending Headlines about DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director purchases: Long‑time director Gregory T. Lucier bought sizable blocks of stock on March 2 and March 3 (27,555 shares at ~$14.24 and 22,445 shares at ~$14.03), raising his ownership to ~50,000 shares — a strong insider confidence signal. InsiderTrades Article
• Positive Sentiment: Barrington Research raised its price target to $17 — an upbeat analyst action that implies meaningful upside relative to current levels and can attract buyer interest. Barrington Research PT Raise
• Positive Sentiment: Zacks upgraded XRAY from “strong sell” to “hold,” removing a negative rating and potentially supporting short‑term sentiment improvement. Zacks Upgrade
• Neutral Sentiment: Mizuho raised its price target to $16 but left a “neutral” rating — modestly positive for price targets but limited catalyst without a rating upgrade. Mizuho Note
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference (Mar 10) — a scheduled event that could provide fresh guidance or color but is not itself a guaranteed catalyst. Conference Notice
• Neutral Sentiment: Fundamental watch‑items: Coverage notes flag international revenue trends and mixed analyst targets (average PT ~$14.42) — useful context for modeling but neither clearly bullish nor bearish on its own. Zacks Analysis
• Neutral Sentiment: Short‑interest reporting appears anomalous (reports showing zero/NaN), so treat any short‑squeeze narratives as unreliable until corrected data is posted.
• Negative Sentiment: Earnings & guidance caveat: The company slightly missed quarterly EPS consensus (by ~$0.01) despite a revenue beat, and FY‑2026 guidance (1.40–1.50 EPS) sits below some sell‑side estimates (~1.84), which could cap upside if analysts lower forecasts. MarketBeat Summary

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of institutional investors have recently modified their holdings of XRAY. Vanguard Group Inc. lifted its stake in shares of DENTSPLY SIRONA by 4.1% in the third quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock valued at $279,263,000 after buying an additional 869,566 shares in the last quarter. First Eagle Investment Management LLC increased its position in shares of DENTSPLY SIRONA by 3.2% during the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after acquiring an additional 458,744 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares during the last quarter. Lazard Asset Management LLC boosted its stake in DENTSPLY SIRONA by 0.9% during the 3rd quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock valued at $129,445,000 after purchasing an additional 92,868 shares during the last quarter. Finally, Armistice Capital LLC boosted its stake in DENTSPLY SIRONA by 27.2% during the 4th quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier’s stock valued at $83,416,000 after purchasing an additional 1,562,000 shares during the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.